Patents by Inventor Christophe Peixoto

Christophe Peixoto has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11718588
    Abstract: The present invention discloses compounds according to Formula I: Wherein R1, R2, R3a, R3b, and Cy are as defined herein. The present invention relates to compounds inhibiting ADAMTS, methods for their production, pharmaceutical compositions comprising the same, and methods of treatment using the same, for the prophylaxis and/or treatment of inflammatory conditions, and/or diseases involving degradation of cartilage and/or disruption of cartilage homeostasis by administering a compound of the invention.
    Type: Grant
    Filed: January 5, 2021
    Date of Patent: August 8, 2023
    Assignee: GALAPAGOS NV
    Inventors: Franck Laurent Brebion, Luke Jonathan Alvey, David Amantini, Frédéric André De Ceuninck, Pierre Marc Marie Joseph Deprez, Romain Luc Marie Gosmini, Hélène Marie Jary, Christophe Peixoto, Iuliana Ecaterina Pop-Botez, Marie Laurence Claire Varin
  • Publication number: 20230022534
    Abstract: The present invention discloses compounds according to Formula I: Wherein R1a, R1b, R2, R4, R5, R6a, R6b, R7, R8, W, X, Cy, and the subscript a are as defined herein. The present invention relates to compounds inhibiting autotaxin (NPP2 or ENPP2), methods for their production, pharmaceutical compositions comprising the same, and methods of treatment using the same, for the prophylaxis and/or treatment of diseases involving fibrotic diseases, proliferative diseases, inflammatory diseases, autoimmune diseases, respiratory diseases, cardiovascular diseases, neurodegenerative diseases, dermatological disorders, and/or abnormal angiogenesis associated diseases by administering the compound of the invention.
    Type: Application
    Filed: June 18, 2021
    Publication date: January 26, 2023
    Applicant: Galapagos NV
    Inventors: Nicolas DESROY, Bertrand HECKMANN, Reginald Christophe Xavier BRYS, Agnès Marie JONCOUR, Christophe PEIXOTO, Xavier Marie BOCK
  • Publication number: 20220402911
    Abstract: The present invention discloses compounds according to Formula I: wherein R1, R2a, X, Y, and Z are as defined herein. The present invention relates to compounds, methods for their production, pharmaceutical compositions comprising the same, and methods of treatment using the same, for the prophylaxis and/or treatment of inflammatory diseases, autoinflammatory diseases, autoimmune diseases, proliferative diseases, fibrotic diseases, transplantation rejection, diseases involving impairment of cartilage turnover, congenital cartilage malformation, diseases involving impairment of bone turnover, diseases associated with hypersecretion of IL-6, diseases associated with hypersecretion of TNF?, interferons, IL-12 and/or IL-23, respiratory diseases, endocrine and/or metabolic diseases, cardiovascular diseases, dermatological diseases, and/or abnormal angiogenesis associated diseases by administering the compound of the invention.
    Type: Application
    Filed: May 29, 2019
    Publication date: December 22, 2022
    Inventors: David AMANTINI, Reginald Christophe Xavier BRYS, Denis BUCHER, Steve Irma Joel DE VOS, Nicolas DESROY, Agnès Marie JONCOUR, Christophe PEIXOTO, Taoues TEMAL-LAÏB, Amynata TIRERA
  • Publication number: 20220340548
    Abstract: The present invention discloses compounds according to Formula I: wherein R1a, R1b, R1c, R2a, W1, W2, X1, X2, X3, Y, and Z are as defined herein. The present invention relates to compounds, methods for their production, pharmaceutical compositions comprising the same, and methods of treatment using the same, for the prophylaxis and/or treatment of inflammatory diseases, autoinflammatory diseases, autoimmune diseases, proliferative diseases, fibrotic diseases, transplantation rejection, diseases involving impairment of cartilage turnover, congenital cartilage malformation, diseases involving impairment of bone turnover, diseases associated with hypersecretion of IL-6, diseases associated with hypersecretion of TNF?, interferons, IL-12 and/or IL-23, respiratory diseases, endocrine and/or metabolic diseases, cardiovascular diseases, dermatological diseases, and/or abnormal angiogenesis associated diseases by administering the compound of the invention.
    Type: Application
    Filed: May 25, 2020
    Publication date: October 27, 2022
    Inventors: Luke Jonathan ALVEY, Denis BUCHER, Nicolas DESROY, Hélène Marie JARY, Christophe PEIXOTO, Taoues TEMAL-LAÏB, Amynata TIRERA, Florence Marie-Emilie BONNATERRE, Béranger DUTHION
  • Publication number: 20220340581
    Abstract: The present invention discloses compounds according to Formula I: wherein R1, R2, R3a, R3b, X, Y1, Y2, Y3, and Z are as defined herein. The present invention relates to compounds, methods for their production, pharmaceutical compositions comprising the same, and methods of treatment using the same, for the prophylaxis and/or treatment of inflammatory diseases, autoinflammatory diseases, autoimmune diseases, proliferative diseases, fibrotic diseases, transplantation rejection, diseases involving impairment of cartilage turnover, congenital cartilage malformation, diseases involving impairment of bone turnover, diseases associated with hypersecretion of TNF?, interferons, IL-6, IL-12 and/or IL-23, respiratory diseases, endocrine and/or metabolic diseases, cardiovascular diseases, dermatological diseases, and/or abnormal angiogenesis associated diseases by administering the compound of the invention.
    Type: Application
    Filed: April 13, 2022
    Publication date: October 27, 2022
    Inventors: Luke Jonathan ALVEY, Denis Maurice ANNOOT, Florence Marie-Emilie BONNATERRE, Denis BUCHER, Béranger DUTHION, Hélène Marie JARY, Christophe PEIXOTO, Taoues TEMAL-LAIB, Amynata TIRERA, Nicolas DESROY
  • Patent number: 11339166
    Abstract: The present invention discloses compounds according to Formula I: wherein R1, R2, R3a, R3b, X, Y1, Y2, Y3, and Z are as defined herein. The present invention relates to compounds, methods for their production, pharmaceutical compositions comprising the same, and methods of treatment using the same, for the prophylaxis and/or treatment of inflammatory diseases, autoinflammatory diseases, autoimmune diseases, proliferative diseases, fibrotic diseases, transplantation rejection, diseases involving impairment of cartilage turnover, congenital cartilage malformation, diseases involving impairment of bone turnover, diseases associated with hypersecretion of TNF?, interferons, IL-6, IL-12 and/or IL-23, respiratory diseases, endocrine and/or metabolic diseases, cardiovascular diseases, dermatological diseases, and/or abnormal angiogenesis associated diseases by administering the compound of the invention.
    Type: Grant
    Filed: November 26, 2018
    Date of Patent: May 24, 2022
    Assignee: GALAPAGOS NV
    Inventors: Luke Jonathan Alvey, Denis Maurice Annoot, Florence Marie-Emilie Bonnaterre, Denis Bucher, Béranger Duthion, Hélène Marie Jary, Christophe Peixoto, Taoues Temal-Laib, Amynata Tirera, Nicolas Desroy
  • Publication number: 20210309614
    Abstract: The present invention discloses compounds according to Formula I: Wherein R1, R2, R3a, R3b, and Cy are as defined herein. The present invention relates to compounds inhibiting ADAMTS, methods for their production, pharmaceutical compositions comprising the same, and methods of treatment using the same, for the prophylaxis and/or treatment of inflammatory conditions, and/or diseases involving degradation of cartilage and/or disruption of cartilage homeostasis by administering a compound of the invention.
    Type: Application
    Filed: January 5, 2021
    Publication date: October 7, 2021
    Inventors: Franck Laurent BREBION, Luke Jonathan ALVEY, David AMANTINI, Frédéric André DE CEUNINCK, Pierre Marc Marie Joseph DEPREZ, Romain Luc Marie GOSMINI, Hélène Marie JARY, Christophe PEIXOTO, Iuliana Ecaterina POP-BOTEZ, Marie Laurence Claire VARIN
  • Patent number: 11072611
    Abstract: The present invention discloses compounds according to Formula I: Wherein R1a, R1b, R2, R4, R5, R6a, R6b, R8, W, X, Cy, and the subscript a are as defined herein. The present invention relates to compounds inhibiting autotaxin (NPP2 or ENPP2), methods for their production, pharmaceutical compositions comprising the same, and methods of treatment using the same, for the prophylaxis and/or treatment of diseases involving fibrotic diseases, proliferative diseases, inflammatory diseases, autoimmune diseases, respiratory diseases, cardiovascular diseases, neurodegenerative diseases, dermatological disorders, and/or abnormal angiogenesis associated diseases by administering the compound of the invention.
    Type: Grant
    Filed: November 13, 2019
    Date of Patent: July 27, 2021
    Assignee: GALAPAGOS NV
    Inventors: Nicolas Desroy, Bertrand Heckmann, Reginald Christophe Xavier Brys, Agnès Marie Joncour, Christophe Peixoto, Xavier Marie Bock
  • Publication number: 20210101903
    Abstract: The present invention discloses compounds according to Formula I: wherein R1, R2, R3a, R3b, X, Y1, Y2, Y3, and Z are as defined herein. The present invention relates to compounds, methods for their production, pharmaceutical compositions comprising the same, and methods of treatment using the same, for the prophylaxis and/or treatment of inflammatory diseases, autoinflammatory diseases, autoimmune diseases, proliferative diseases, fibrotic diseases, transplantation rejection, diseases involving impairment of cartilage turnover, congenital cartilage malformation, diseases involving impairment of bone turnover, diseases associated with hypersecretion of TNF?, interferons, IL-6, IL-12 and/or IL-23, respiratory diseases, endocrine and/or metabolic diseases, cardiovascular diseases, dermatological diseases, and/or abnormal angiogenesis associated diseases by administering the compound of the invention.
    Type: Application
    Filed: November 26, 2018
    Publication date: April 8, 2021
    Inventors: Luke Jonathan ALVEY, Denis Maurice ANNOOT, Florence Marie-Emilie BONNATERRE, Denis BUCHER, Béranger DUTHION, Hélène Marie JARY, Christophe PEIXOTO, Taoues TEMAL-LAIB, Amynata TIRERA, Nicolas DESROY
  • Patent number: 10941117
    Abstract: The present invention discloses compounds according to Formula I: Wherein R1, R2, R3a, R3b, and Cy are as defined herein. The present invention relates to compounds inhibiting ADAMTS, methods for their production, pharmaceutical compositions comprising the same, and methods of treatment using the same, for the prophylaxis and/or treatment of inflammatory conditions, and/or diseases involving degradation of cartilage and/or disruption of cartilage homeostasis by administering a compound of the invention.
    Type: Grant
    Filed: October 15, 2019
    Date of Patent: March 9, 2021
    Assignees: GALAPAGOS NV, LES LABORATORIES SERVIER
    Inventors: Franck Laurent Brebion, Luke Jonathan Alvey, David Amantini, Frédéric André De Ceuninck, Pierre Marc Marie Joseph Deprez, Romain Luc Marie Gosmini, Hélène Marie Jary, Christophe Peixoto, Iuliana Ecaterina Pop-Botez, Marie Laurence Claire Varin
  • Patent number: 10829478
    Abstract: The present invention discloses compounds according to Formula I: Wherein R1, R2, R3a, R3b, R6a, R6b, the subscript n and Cy are as defined herein. The present invention relates to compounds inhibiting ADAMTS, methods for their production, pharmaceutical compositions comprising the same, and methods of treatment using the same, for the prophylaxis and/or treatment of inflammatory diseases, and/or diseases involving degradation of cartilage and/or disruption of cartilage homeostasis by administering the compound of the invention.
    Type: Grant
    Filed: June 1, 2017
    Date of Patent: November 10, 2020
    Assignee: GALAPAGOS NV
    Inventors: Frédéric Gilbert Labéguère, Rama Heng, Frédéric André De Ceuninck, Luke Jonathan Alvey, David Amantini, Franck Laurent Brebion, Pierre Marc Marie Joseph Deprez, Romain Luc Marie Gosmini, Hélène Marie Jary, Christophe Peixoto, Iuliana Ecaterina Pop-Botez, Marie Laurence Claire Varin
  • Publication number: 20200239466
    Abstract: The present invention discloses compounds according to Formula I: Wherein R1a, R1b, R2, R4, R5, R6a, R6b, R8, W, X, Cy, and the subscript a are as defined herein. The present invention relates to compounds inhibiting autotaxin (NPP2 or ENPP2), methods for their production, pharmaceutical compositions comprising the same, and methods of treatment using the same, for the prophylaxis and/or treatment of diseases involving fibrotic diseases, proliferative diseases, inflammatory diseases, autoimmune diseases, respiratory diseases, cardiovascular diseases, neurodegenerative diseases, dermatological disorders, and/or abnormal angiogenesis associated diseases by administering the compound of the invention.
    Type: Application
    Filed: November 13, 2019
    Publication date: July 30, 2020
    Applicant: Galapagos NV
    Inventors: Nicolas DESROY, Bertrand HECKMANN, Reginald Christophe Xavier BRYS, Agnès Marie JONCOUR, Christophe PEIXOTO, Xavier Marie BOCK
  • Publication number: 20200216397
    Abstract: The present invention discloses compounds according to Formula I: Wherein R1, R2, R3a, R3b, and Cy are as defined herein. The present invention relates to compounds inhibiting ADAMTS, methods for their production, pharmaceutical compositions comprising the same, and methods of treatment using the same, for the prophylaxis and/or treatment of inflammatory conditions, and/or diseases involving degradation of cartilage and/or disruption of cartilage homeostasis by administering a compound of the invention.
    Type: Application
    Filed: October 15, 2019
    Publication date: July 9, 2020
    Inventors: Franck Laurent BREBION, Luke Jonathan ALVEY, David AMANTINI, Frédéric André DE CEUNINCK, Pierre Marc Marie Joseph DEPREZ, Romain Luc Marie GOSMINI, Hélène Marie JARY, Christophe PEIXOTO, Iuliana Ecaterina POP-BOTEZ, Marie Laurence Claire VARIN
  • Patent number: 10550100
    Abstract: The present invention discloses compounds according to Formula I: Wherein R1, R2, R3a, R3b, R6, Cy, and the subscript n are as defined herein. The present invention relates to compounds inhibiting ADAMTS, methods for their production, pharmaceutical compositions comprising the same, and methods of treatment using the same, for the prophylaxis and/or treatment of inflammatory diseases, and/or diseases involving degradation of cartilage and/or disruption of cartilage homeostasis by administering the compound of the invention.
    Type: Grant
    Filed: June 1, 2017
    Date of Patent: February 4, 2020
    Assignee: GALAPAGOS NV
    Inventors: Frédéric Gilbert Labéguère, Rama Heng, Frédéric André De Ceuninck, Luke Jonathan Alvey, David Amantini, Franck Laurent Brebion, Pierre Marc Marie Joseph Deprez, Romain Luc Marie Gosmini, Hélène Marie Jary, Christophe Peixoto, Iuliana Ecaterina Pop-Botez, Marie Laurence Claire Varin
  • Patent number: 10526329
    Abstract: The present invention discloses compounds according to Formula I: Wherein R1a, R1b, R2, R4, R5, R6a, R6b, R7, R8, W, X, Cy, and the subscript a are as defined herein. The present invention relates to compounds inhibiting autotaxin (NPP2 or ENPP2), methods for their production, pharmaceutical compositions comprising the same, and methods of treatment using the same, for the prophylaxis and/or treatment of diseases involving fibrotic diseases, proliferative diseases, inflammatory diseases, autoimmune diseases, respiratory diseases, cardiovascular diseases, neurodegenerative diseases, dermatological disorders, and/or abnormal angiogenesis associated diseases by administering the compound of the invention.
    Type: Grant
    Filed: September 28, 2018
    Date of Patent: January 7, 2020
    Assignee: GALAPAGOS NV
    Inventors: Nicolas Desroy, Bertrand Heckmann, Reginald Christophe Xavier Brys, Agnès Marie Joncour, Christophe Peixoto, Xavier Marie Bock
  • Patent number: 10487060
    Abstract: The present invention discloses compounds according to Formula I: Wherein R1, R2, R3a, R3b, and Cy are as defined herein. The present invention relates to compounds inhibiting ADAMTS, methods for their production, pharmaceutical compositions comprising the same, and methods of treatment using the same, for the prophylaxis and/or treatment of inflammatory conditions, and/or diseases involving degradation of cartilage and/or disruption of cartilage homeostasis by administering a compound of the invention.
    Type: Grant
    Filed: February 14, 2018
    Date of Patent: November 26, 2019
    Assignees: GALAPAGOS NV, LES LABORATOIRES SERVIER
    Inventors: Franck Laurent Brebion, Luke Jonathan Alvey, David Amantini, Frédéric André De Ceuninck, Pierre Marc Marie Joseph Deprez, Romain Luc Marie Gosmini, Hélène Marie Jary, Christophe Peixoto, Iuliana Ecaterina Pop-Botez, Marie Laurence Claire Varin
  • Publication number: 20190315719
    Abstract: The present invention discloses compounds according to Formula I: Wherein R1, R2, R3a, R3b, R6a, R6b, the subscript n and Cy are as defined herein. The present invention relates to compounds inhibiting ADAMTS, methods for their production, pharmaceutical compositions comprising the same, and methods of treatment using the same, for the prophylaxis and/or treatment of inflammatory diseases, and/or diseases involving degradation of cartilage and/or disruption of cartilage homeostasis by administering the compound of the invention.
    Type: Application
    Filed: June 1, 2017
    Publication date: October 17, 2019
    Inventors: Frédéric Gilbert LABÉGUÈRE, Rama HENG, Frédéric André DE CEUNINCK, Luke Jonathan ALVEY, David AMANTINI, Franck Laurent BREBION, Pierre Marc Marie Joseph DEPREZ, Romain Luc Marie GOSMINI, Hélène Marie JARY, Christophe PEIXOTO, Iuliana Ecaterina POP-BOTEZ, Marie Laurence Claire VARIN
  • Publication number: 20190300503
    Abstract: The present invention discloses compounds according to Formula I: Wherein R1, R2, R3a, R3b, R6, Cy, and the subscript n are as defined herein. The present invention relates to compounds inhibiting ADAMTS, methods for their production, pharmaceutical compositions comprising the same, and methods of treatment using the same, for the prophylaxis and/or treatment of inflammatory diseases, and/or diseases involving degradation of cartilage and/or disruption of cartilage homeostasis by administering the compound of the invention.
    Type: Application
    Filed: June 1, 2017
    Publication date: October 3, 2019
    Inventors: Frédéric Gilbert LABÉGUÈRE, Rama HENG, Frédéric André DE CEUNINCK, Luke Jonathan ALVEY, David AMANTINI, Franck Laurent BREBION, Pierre Marc Marie Joseph DEPREZ, Romain Luc Marie GOSMINI, Hélène Marie JARY, Christophe PEIXOTO, Iuliana Ecaterina POP-BOTEZ, Marie Laurence Claire VARIN
  • Publication number: 20190169184
    Abstract: The present invention discloses compounds according to Formula I: Wherein R1a, R1b, R2, R4, R5, R6a, R6b, R7, R8, W, X, Cy, and the subscript a are as defined herein. The present invention relates to compounds inhibiting autotaxin (NPP2 or ENPP2), methods for their production, pharmaceutical compositions comprising the same, and methods of treatment using the same, for the prophylaxis and/or treatment of diseases involving fibrotic diseases, proliferative diseases, inflammatory diseases, autoimmune diseases, respiratory diseases, cardiovascular diseases, neurodegenerative diseases, dermatological disorders, and/or abnormal angiogenesis associated diseases by administering the compound of the invention.
    Type: Application
    Filed: September 28, 2018
    Publication date: June 6, 2019
    Applicant: Galapagos NV
    Inventors: Nicolas DESROY, Bertrand HECKMANN, Reginald Christophe Xavier BRYS, Agnès Marie JONCOUR, Christophe PEIXOTO, Xavier Marie BOCK
  • Publication number: 20190167640
    Abstract: The present invention relates to, inter alia, treatment of muscle dystrophy (e.g., Duchenne Muscular Dystrophy), for example, using a composition, e.g., a composition comprising Compound (I), or a pharmaceutically acceptable salt, prodrug or metabolite thereof.
    Type: Application
    Filed: October 24, 2018
    Publication date: June 6, 2019
    Inventors: Ernest D. Bush, Francois Nique, Catherine Jagerschmidt, Florence Sylvie Namour, Roland Blanque, Jean-Michel Lefrancois, Christophe Peixoto, Pierre Deprez, Nicholas Triballeau, Piet Tom Burt Paul Wigerinck